A Single-Blind randomized trial of High-Dose versus Standard-Dose Inactivated Influenza Vaccine in Adult Patients Treated for an Hematological Cancer (Flu-Hemato-Rando study)
- Conditions
- Hematological cancerTherapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2023-505357-40-00
- Lead Sponsor
- CHU De Liege
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Patients under treatment for: a multiple myeloma, or a B-cell malignancy (including patients given rituximab in the 6 months prior to vaccine even if no additional treatment given)., or a myeloid malignancy (hydroxyurea or tyrosine kinase inhibitors are not be considered as a treatment” for the current study in contrast to JAK inhibitors or azacitidine) or standard chemotherapy, Age > or = 18 years at inclusion, Written informed consent
HIV seropositivity, Pregnancy, Egg allergy or allergy to previous influenza vaccine, IVIg in the past 30 days or planning to receive IVIg in the 4 weeks after vaccination, Prior post-transplant IIV vaccination in the same season, Severe Heart failure (ejection fraction < 35%) at the last examination
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method